In vitro Studies of Chitosan-based Muitifunctional Drug Delivery Nanosystem

制备了一种壳聚糖基多功能纳米药物载体系统,并探讨了其体外释药性质.合成了甲氨蝶呤-壳聚糖偶联物(MTX-CS),甲氨喋呤(MTX)的取代度为6.3％;MTX-CS具有两亲性,在水性介质中能自组装形成纳米粒子,平均粒径为(269.5±18.3) nm,zeta电位为(25.7±0.9) mV.MTX-CS纳米粒子能有效包载抗血管生成药Combretastatin A-4(CA-4),当药物/载体材料投料比为1∶4时,载药量为15.7％,包封率为62.8％.体外释放实验结果显示,CA-4释放较快,MTX释放缓慢,有利于发挥2种药物的协同抗肿瘤作用.     

壳聚糖/乙酰半胱氨酸纳米粒子的性质及体外释药性

制备了一种基于壳聚糖/乙酰半胱氨酸偶合物(CS-NAC)的新型巯基纳米粒子并进行了结构表征, 同时对纳米粒子的黏附性、溶胀性和药物释放进行了测试. 结果表明, 纳米粒子具有较小的粒径(140~210 nm)和正的表面电位(19.5~31.7 mV), 胰岛素的载药量达到13%~42%. 这些性质随着巯基含量的变化而变化. 与壳聚糖纳米粒子相比, 巯基壳聚糖纳米粒子表现出了更强更快的黏附性质. 体外释放研究结果表明, 巯基壳聚糖纳米粒子的胰岛素释放具有pH响应性. 在pH=6.8时, 15 min即能释放58.6 %的胰岛素; 而在pH=5.4时, 24 h内仅有不到40%的胰岛素被释放. 因此, CS-NAC纳米粒子用于胰岛素的黏膜给药体系具有很好的应用前景.     

可生物降解固体脂质纳米粒的制备、表征及药物的体外释放

以可生物降解材料硬脂酸为载体, 以葛根总黄酮为模型药物, 采用乳化蒸发-低温固化法制备固体脂质纳米粒. 采用透射电镜研究载药纳米粒形态, 激光粒度分析仪测定其粒径, X射线衍射仪进行物相鉴别, 并对纳米粒的包封率及体外释药特性等进行了研究. 分析结果表明, 所制备硬脂酸固态脂质纳米粒为类球实体, 粒径分布比较均匀, 平均粒径为(263.82±3.6) nm, 包封率为(67.53±0.12)%. X射线衍射分析证明药物以分子或细小粒子分散于脂质骨架中. 体外释药研究结果表明, 纳米粒体外释药先快后慢, 12 h累积释药50%, 包封于降解材料骨架内的药物通过骨架溶蚀缓慢释放. 药物的体外释放符合Higuchi方程.     

羧甲基壳聚糖-熊果酸纳米载药粒子的合成及性能研究

选择水溶性羧甲基壳聚糖(CMCS)-聚乙二醇(PEG)作为载药分子链,叶酸(FA)作为靶向分子,利用pH感应酯键连接药物分子熊果酸(UA),通过吸附自组装包裹10-羟基喜树碱(HCPT),合成了一种抗肿瘤叶酸-聚乙二醇-羧甲基壳聚糖-熊果酸/10-羟基喜树碱~1H-NMR及TEM表征FA-PEG-CMCS-UA/HCPT纳米药物粒子结构和形态。核磁共振谱表明,UA是以酯键连接CMCS,透射电镜图显示纳米粒子呈球形;UA和HCPT的载药量分别为(6.4±0.1)%和(14.1±0.2)%;在pH值为7.4和5.5且PBS缓冲液中体外药物释放达到330h时,UA的累积释放率分别为70.2%和85.1%,HCPT的累积释放率达到73.8%和86.6%。     

壳聚糖-g-聚甲基丙烯酸凝胶粒的制备及其药物释放行为

以壳聚糖和甲基丙烯酸为原料,硝酸铈铵为引发剂,合成了不同接枝率的壳聚糖-g-聚甲基丙烯酸(CS-g-PMAA),用FTIR、1H NMR和元素分析表征了产物的结构,以柠檬酸三钠和戊二醛为交联剂制备了具有核壳结构的CS-g-PMAA载药体系。 用UV/Vis检测了CS-g-PMAA粒子对模型药物的释放行为。 结果表明,CS-g-PMAA接枝率为12.21%时药物释放速率最慢,其在pH=1.8介质中药物累积释放量(11 h)为44.18%,而壳聚糖粒子的累积释放量高达65.24%,即接枝改性壳聚糖粒子对药物的缓慢控制释放性能较好; CS-g-PMAA粒子的释药行为还依赖于介质的pH值和盐浓度,在低pH值和低盐浓度下,药物释放速率较快;酶环境下由于载体材料的降解使药物释放速率加快。 分析了不同条件下CS-g-PMAA载药粒子中药物的释放机理。     

抗癌载药体系Fe_3O_4@ZIF-8@PA的合成及药物释放

采用溶剂热法合成磁性Fe_3O_4纳米粒子,并以此为基底设计制备了一种具有pH响应核壳结构的磁性纳米复合材料Fe_3O_4@ZIF-8@PA.该材料的比饱和磁化强度可达35.46 A·m2/g,具有良好的磁性.Fe_3O_4纳米粒子呈球型结构,分散性良好.与基底相比,复合微球的粒径尺寸明显增大,但依然符合载体材料的理想尺寸且分布均匀.此外,载体具有多孔结构,表面积较大,载药效率和载药量分别高达96.4%和144.6 mg/g.在pH为7.4和5.0的条件下对载药纳米粒子进行了药物释放研究.24 h内,粒子在2种pH下累计释放量分别为39.8%和78.6%.通过药物缓释验证了载体的pH响应性能.在实验中引入了对癌细胞具有杀伤作用的植酸,使合成的载体具有一定的抗癌作用.同时采用四甲基偶氮唑盐(MTT)法对人骨肉瘤细胞(MG-63)进行了体外分析实验,证实材料与抗癌药物阿霉素(DOX)之间存在着一定的协同抗癌效果.     

α-环糊精/聚乙二醇自组装超分子纳米药物载体

研究了一种新型超分子纳米药物载体的制备方法及其药物释放性能. 将α-环糊精(α-CD)穿入肉桂酸改性的PEG分子链形成包含复合物(inclusion complex, IC), 通过超分子自组装成为纳米粒子. 将抗肿瘤药物阿霉素负载到纳米粒子中, 研究药物释放行为及其对肿瘤细胞的抑制效果. 以核磁共振(1H NMR)、X射线衍射(XRD)、紫外吸收光谱(UV)、动态光散射(DLS)、扫描电镜(SEM)、透射电镜(TEM)和原子力显微镜(AFM)表征了纳米粒子的结构和形貌, 用激光共聚焦显微镜(Confocal)研究了载药纳米粒子在细胞内的分布及其对肿瘤细胞的抑制效果. 结果显示超分子纳米粒子具有很好的生物相容性和药物缓释作用, 载药纳米粒子对肿瘤细胞具有很好的杀伤效果.     

同源细胞膜包覆智能释药纳米粒用于肝癌靶向治疗

近年来,纳米药物递送系统在癌症治疗方面的应用受到广泛关注。 传统的纳米药物递送系统存在生物相容性差、靶向性缺乏、在肿瘤部位释药缓慢等问题。 本文设计制备了一种同源细胞膜(M)包覆、癌细胞还原微环境控制释药的脂质体纳米粒子(命名为P-ss-G/D/Sf@M)来递送肝癌治疗药物索拉非尼(Sf)用于肝癌的靶向治疗。 利用薄膜水化法结合静电吸附及过膜挤压法制备包覆细胞膜的空白(P-ss-G/D@M)及载药(P-ss-G/D/Sf@M)纳米粒子。 P-ss-G/D/Sf@M对Sf的载药量为7.2%,包封率为79.9%。 体外释药结果显示,P-ss-G/D/Sf@M在还原条件下会加快药物的释放,48 h时药物释放量达到65%以上,较非还原条件下释药量提高了25%。 体外细胞实验结果证明,包覆肝癌细胞膜的纳米粒子更易被肝癌细胞摄取,表现了对肝癌细胞的靶向性,同时在肿瘤细胞高浓度谷胱甘肽(GSH)还原环境作用下,纳米粒子中的二硫键断裂,迅速释放药物,与非还原敏感载药纳米粒子相比,显著抑制肝癌细胞生长,提高细胞凋亡率。 因此,本文制备的同源细胞膜包覆的智能释药载体有可能用于今后的癌症治疗中。     

基于聚(L-谷氨酸)树状分子的智能药物释放系统研究

以天然氨基酸L-谷氨酸为原料,通过收敛法合成了聚(L-谷氨酸)树状分子,通过半胱氨酸将抗肿瘤药物甲氨蝶呤( MTX)键合到聚(L-谷氨酸)树状分子上,构建氧化还原敏感的药物传输系统.用核磁(1H～NMR)等对载体以及载药粒子进行了表征.体外释放研究发现,载药粒子具有良好的氧化还原响应性,在不同浓度的还原剂二硫苏糖醇(D...     

具有靶向抗癌功能的O-CMC磁性纳米载体系统的制备

首次以O_羧甲基壳聚糖 (O_CMC)为原料 ,制备出具有超顺磁特性的正电性纳米载体 ,并将其与抗癌药物甲氨喋呤 (MTX)结合 ,构建成平均粒径 5 0nm的具有磁靶向抗癌功能的纳米载体系统。该载体在人体血液微循环模型进行的体外靶向定位试验中呈现良好的磁感应性。体外抑瘤试验结果表明 ,该磁性纳米载药体系中MTX保持了较好的抗肿瘤特性。     

Simple surface functionalization of magnetic nanoparticles with methotrexate-conjugated bovine serum albumin as a biocompatible drug delivery vehicle

Magnetic nanoparticles (MNPs) functionalized with methotrexate (MTX)-conjugated bovine serum albumin (BSA) as a biocompatible drug delivery vehicle were synthesized using a facile method. Characterization of the functionalized MNPs (Fe₃O₄@BSA-MTX NPs) was performed using various techniques including UV–visible spectroscopy, dynamic light scattering, vibrating sample magnetometry and X-ray diffraction. The particle size and zeta potential of Fe₃O₄@BSA-MTX NPs were 105.7 ± 3.81 nm (mean ± SD) and −18.2 mV, respectively. MTX release from Fe₃O₄@BSA-MTX NPs showed an enzyme-dependent release pattern. Hemo-biocompatibility of Fe₃O₄@BSA-MTX NPs was confirmed using hemolysis test. In addition, the cytotoxicity of functionalized MNPs and free MTX against MCF-7 cell line was investigated using MTT assay. The results of experiments revealed that the Fe₃O₄@BSA-MTX NPs as a biocompatible carrier could improve the therapeutic effect of MTX.     

Chitosan-Linseed mucilage polyelectrolyte complex nanoparticles of Methotrexate: In vitro cytotoxic efficacy and toxicological studies

The goal of this research was to develop, fabricate and analyze polymeric nanoparticles for the administration of methotrexate (MTX). Linseed mucilage and chitosan nanoparticles (NPs) were prepared using a slightly modified polyelectrolyte complex (PEC) method. The size, shape, and encapsulation effectiveness of the resultant nanoparticles were measured. MTX release profiles at gastrointestinal pH (1.2 and 7.4) and tumor pH (5.5) were examined to determine the targeted potential of NPs as pH-responsive nanocarriers. Zeta analysis showed that nanoparticles prepared by PEC have a size range of 192.1 nm to 246 nm, and PDI was 0.3 of the optimized formulation, which showed homogenous nature of prepared nanoparticles formulation. The findings demonstrated that NPs have a low polydispersity index and a positive zeta potential (PDI). The in-vitro release of the drug indicated a pH-dependent, sustained drug release up to 24 h. Blank LSMCSNPs had almost no in-vivo cytotoxicity for 14 days, while optimum MTX loaded NPs had strong antitumor effects on HepG2 and MCF-7 cells as measured by the MTT assay. Cell apoptosis induction was also checked and MCF-7 cells treated with MTX-LSMCSNPs had a significantly greater rate of apoptosis (21.2 %) than those treated with MTX alone (14.14 %). The findings show that LSMCSNPs could be a potential delivery mechanism for methotrexate to cancer cells in a secure, steady, and ideally controlled manner to improve therapeutic outcomes.     

Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells

A magnetic nanoparticle conjugate was developed that can potentially serve both as a contrast enhancement agent in magnetic resonance imaging and as a drug carrier in controlled drug delivery, targeted at cancer diagnostics and therapeutics. The conjugate is made of iron oxide nanoparticles covalently bound with methotrexate (MTX), a chemotherapeutic drug that can target many cancer cells whose surfaces are overexpressed by folate receptors. The nanoparticles were first surface-modified with (3-aminopropyl)trimethoxysilane to form a self-assembled monolayer and subsequently conjugated with MTX through amidation between the carboxylic acid end groups on MTX and the amine groups on the particle surface. Drug release experiments demonstrated that MTX was cleaved from the nanoparticles under low pH conditions mimicking the intracellular conditions in the lysosome. Cellular viability studies in human breast cancer cells (MCF-7) and human cervical cancer cells (HeLa) further demonstrated the effectiveness of such chemical cleavage of MTX inside the target cells through the action of intracellular enzymes. The intracellular trafficking model proposed was supported through nanoparticle uptake studies which demonstrated that cells expressing the human folate receptor internalized a higher level of nanoparticles than negative control cells.     

Self-aggregated nanoparticles from methoxy poly(ethylene glycol)-modified chitosan: synthesis; characterization; aggregation and methotrexate release in vitro

Methoxy poly(ethylene glycol)-grafted-chitosan (mPEG-g-CS) conjugates were synthesized by formaldehyde linking method and characterized by Fourier transform infrared (FT-IR) and proton nuclear magnetic resonance (¹H-NMR). The degree of substitution (DS) of methoxy poly (ethylene glycol) (mPEG) in the mPEG-g-CS molecules determined by ¹H-NMR ranged from 19% to 42%. The critical aggregation concentration (CAC) was determined by fluorescence spectroscopy using pyrene as fluorescence probe and its value was 0.07 mg/mL in water. mPEG-g-CS formed monodisperse self-aggregated nanoparticles with a roughly spherical shape and a mean diameter of 261.9 nm were prepared by the dialysis method. mPEG-g-CS self-aggregated nanoparticles were used as carriers of poorly water-soluble anticancer drug methotrexate (MTX). MTX was physically entrapped inside mPEG-g-CS self-aggregated nanoparticles by dialysis method and the characteristics of MTX-loaded mPEG-g-CS self-aggregated nanoparticles were analyzed using dynamic laser light scattering (DLLS), transmission electron microscopy (TEM). Moreover, in vitro release behavior of MTX was also investigated and the results showed that MTX was continuously released more than 50% in 48 h.     

Synthesis and characterization of folic acid‐modified carboxymethyl chitosan‐ursolic acid targeted nano‐drug carrier for the delivery of ursolic acid and 10‐hydroxycamptothecin

Carboxymethyl chitosan (CMCS), as a water‐soluble, biocompatible, and biodegradable polymer, is an excellent carrier for a sustained drug delivery system. In this study, a amphiphilic carboxymethyl chitosan‐ursolic acid nano‐drug carrier modified by folic acid (FPCU) were prepared, and then the nano‐drug carrier wrapped another anticancer drug 10‐hydroxycamptothecin were self‐assembled into nanoparticles (FPCU/HCPT NPs). The FPCU/HCPT NPs had a suitable size, high drug loading efficiency of ursolic acid (6.4%) and 10‐hydroxycamptothecin (14.1%). The drug release study in vitro indicated that the nanoparticles have obviously sustained effect and pH sensitive behaviors, the drug release amount was higher at pH 5.5 than at pH 7.4. in vitro and in vivo study showed that the nanoparticles displayed a high antitumor efficiency to tumor cells compared with free drug. The nano delivery system as a carrier for ursolic acid (UA) and 10‐hydroxycamptothecin (HCPT) has good application prospects in cancer treatment.     

Construction of a pH-responsive drug delivery platform based on the hybrid of mesoporous silica and chitosan

Mesoporous silica nanoparticles (MSN) have been widely used for drug delivery due to their large specific surface area and excellent biocompatibility. However, the mesoporous structure of MSN would lead to the inevitable “premature release” of the drugs, and therefore the modification of MSN for controlled delivery seems to be a necessary step. Herein, chitosan (CS) was used for the surface functionalization of MSN via amidation reaction, and the introduced CS could function as a “gatekeeper” and the drug of methotrexate (MTX) might be encapsulated in the mesopores of MSN. As a result, the “premature release” of the encapsulated MTX could be effectively circumvented with the aid of the CS cap. More importantly, the drug delivery from the hybrid of MSN and CS (MSN/CS) can be endowed with pH-sensitivity by the introduction of CS because the amide bonding between CS and MSN is highly pH-sensitive. The cumulative release of MTX from the MSN/CS is more pronounced at pH 5.0 (80.86%) than those at pH 6.8 (40.46%) and pH 7.4 (18.25%).     

Methotrexate-incorporated polymeric nanoparticles of methoxy poly(ethylene glycol)-grafted chitosan

We prepared methotrexate (MTX)-encapsulated polymeric nanoparticles using methoxy poly(ethylene glycol) (MPEG)-grafted chitosan (ChitoPEG) copolymer. MTX-encapsulated polymeric nanoparticles of ChitoPEG copolymer has around 50–300 nm in particle size and showed spherical shape when observed by transmission electron microscope (TEM). In ¹H nuclear magnetic resonance (NMR) study, the specific peaks of MTX and chitosan as a drug carrying inner-core disappeared at D₂O and only the specific peak of MPEG was observed, while specific peaks of MPEG, MTX, and chitosan appeared in DCl/D₂O mixtures. These results indicated that MTX was complexed with chitosan and then core–shell type nanoparticles had formed in aqueous environment, i.e., MTX/chitosan complexes composed of inner-core and MPEG composed of outer-shell of the nanoparticles. Loading efficiency of MTX in the polymeric nanoparticles was 94% (w/w) of ChitoPEG-1, 91.1% (w/w) of ChitoPEG-2, 90.1% (w/w) of ChitoPEG-3 and 65.2% (w/w) of ChitoPEG-4, expectively. The higher the drug feeding ratio, the higher the drug content and the lower the loading efficiency. The higher the MPEG graft ratio in the copolymer, the lower the drug content and loading efficiency. Drug contents evaluated by ¹H NMR were the same as found by UV spectrophotometer.     

Gelatin-coated gold nanoparticles as an effective pH-sensitive methotrexate drug delivery system for breast cancer treatment

The present study investigates the synthesis and effectiveness of gold/gelatin nanoparticles (NPs) biopolymer as a carrier for methotrexate (MTX) drug. Two different shapes of gold particles, including spherical AuNPs (50 & 100 nm) and gold nanorods (AuNRs) with three different sizes (20, 50 and 100 nm length) were synthesized using the chemical reduction method. The effect of AuNPs size and shape on the entrapment efficiency (E.E), the release rate of the drug, and cellular uptake were investigated. The surfaces of both AuNPs and AuNRs were coated with a gelatin biopolymer, and the stability and property of the generated compounds were studied. Moreover, MTX as a chemotherapeutic agent was loaded on the gelatin-coated AuNPs/AuNRs complexes. The physicochemical properties of the gelatin-coated AuNPs/AuNRs complexes were studied using ultraviolet-visible (UV–Vis) spectroscopy, dynamic light scattering (DLS), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and Fourier transform infrared (FT-IR) spectroscopy. The E.E and MTX release behavior from the complexes at pH values of 7.4 and 5.4 and temperatures of 37 and 40 °C were investigated in vitro. The cytotoxic effects of AuNPs, AuNPs-Gelatin, AuNPs-Gelatin-MTX, AuNRs, AuNRs-Gelatin, AuNRs-Gelatin-MTX and free MTX were studied. The results indicated that the E.E of AuNPs was higher than that of AuNRs. The highest release rate of the drug was related to the AuNR1-gelatin complex (pH 5.4 and temperature of 40 °C). In addition, MTX loaded AuNR2-gelatin showed the highest cytotoxic effect on the MCF-7 breast cancer cell line so that even its cell cytotoxicity was more than that of the free drug.     

基于磷酸化修饰的核/壳硅纳米颗粒药物缓释体研究

采用反相微乳液体系中功能化基团同步修饰方法制备了包载抗肿瘤药物平阳霉素(PYM)的磷酸化核/壳硅纳米颗粒(PYM-PO4SiNP), 考察了不同量的磷酸化修饰试剂对PYM-PO4SiNP的影响. 结果表明, 随着磷酸化修饰试剂量的增加, 制备的PYM-PO4SiNP的电位逐渐降低, 其包载的PYM 的释放速率逐渐加快, 但对颗粒的粒径没有明显影响. 本文选择能使药物平稳、缓慢释放的磷酸化修饰试剂用量, 制备了稳定性好、药物缓释时间长的PYM-PO4SiNP, 其载药量和包封率分别为7.2%和37.81%, 通过与CNE-2细胞共培育后, 可以使CNE-2细胞的存活率逐渐下降, 而磷酸化核/壳硅纳米颗粒PO4SiNP载体本身是没有毒性的. 这一研究工作的开展拓宽了核/壳硅纳米颗粒在药物载体领域中的应用.